CY1125020T1 - Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων - Google Patents

Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων

Info

Publication number
CY1125020T1
CY1125020T1 CY20221100142T CY221100142T CY1125020T1 CY 1125020 T1 CY1125020 T1 CY 1125020T1 CY 20221100142 T CY20221100142 T CY 20221100142T CY 221100142 T CY221100142 T CY 221100142T CY 1125020 T1 CY1125020 T1 CY 1125020T1
Authority
CY
Cyprus
Prior art keywords
prostate cancer
whole blood
methods
prediction
detection
Prior art date
Application number
CY20221100142T
Other languages
English (en)
Inventor
Deborah Ricci
Michael Gormley
Shibu THOMAS
Yashoda RAJPUROHIT
Michael Schaffer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CY1125020T1 publication Critical patent/CY1125020T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Παρέχονται mRNA βιοδείκτες βασιζόμενοι σε ολικό αίμα, για την πρόβλεψη του καρκίνου προστάτη και μέθοδοι ανίχνευσης αυτών. Οι αποκαλυπτόμενοι mRNA δείκτες και μέθοδοι επιτρέπουν την ταυτοποίηση/διάγνωση ασθενούς με καρκίνο προστάτη, την ταυτοποίηση ασθενούς με καρκίνο προστάτη υψηλής επικινδυνότητας/με πρόβλεψη καρκίνου προστάτη υψηλής επικινδυνότητας, και αγωγή ασθενούς με καρκίνο προστάτη. Επίσης παρέχονται γονιδιοψηφίδες περιλαμβάνουσες τους αποκαλυπτόμενους βασιζόμενους σε ολικό αίμα mRNA βιοδείκτες.
CY20221100142T 2015-03-12 2022-02-21 Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων CY1125020T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562132064P 2015-03-12 2015-03-12
PCT/US2016/022004 WO2016145308A2 (en) 2015-03-12 2016-03-11 Whole blood based mrna markers for predicting prostate cancer and methods of detecting the same

Publications (1)

Publication Number Publication Date
CY1125020T1 true CY1125020T1 (el) 2023-03-24

Family

ID=55642872

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100142T CY1125020T1 (el) 2015-03-12 2022-02-21 Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων

Country Status (19)

Country Link
US (1) US20160304962A1 (el)
EP (1) EP3268493B1 (el)
JP (1) JP2018507702A (el)
KR (1) KR20170136525A (el)
CN (1) CN107567502A (el)
CA (1) CA2979226A1 (el)
CY (1) CY1125020T1 (el)
DK (1) DK3268493T3 (el)
ES (1) ES2905163T3 (el)
HR (1) HRP20220128T1 (el)
HU (1) HUE058025T2 (el)
IL (1) IL254119A0 (el)
LT (1) LT3268493T (el)
MA (1) MA45480A (el)
PL (1) PL3268493T3 (el)
PT (1) PT3268493T (el)
RS (1) RS62972B1 (el)
SI (1) SI3268493T1 (el)
WO (1) WO2016145308A2 (el)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7144934B2 (ja) 2015-03-25 2022-09-30 ザ ジェネラル ホスピタル コーポレイション 血液試料中の循環腫瘍細胞のデジタル分析
EP3532642B1 (en) * 2016-10-27 2021-12-08 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
CN107338319A (zh) * 2017-08-25 2017-11-10 天津艾至恩医疗科技有限公司 一种核苷酸引物及预测前列腺癌去势术预后的基因多态性检测试剂盒
CN110760585B (zh) * 2019-11-07 2022-12-09 深圳市华启生物科技有限公司 前列腺癌生物标志物及其应用
CN111500728A (zh) * 2020-05-13 2020-08-07 无锡市申瑞生物制品有限公司 检测人ar-v7及ar基因表达的引物探针组合物、试剂盒及检测方法
WO2023220314A1 (en) * 2022-05-12 2023-11-16 Veracyte SD, Inc. Prognosis and treatment of molecular subtypes of prostate cancer
KR20240022906A (ko) * 2022-08-12 2024-02-20 (주)맥시온 암 진단용 다중 바이오마커 및 이의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3062106B1 (en) * 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
CA2882253C (en) * 2012-08-17 2021-02-09 Memorial Sloan-Kettering Cancer Center Gene expression profile associated with prostate cancer
JP6663347B2 (ja) * 2013-03-15 2020-03-11 ヤンセン ファーマシューティカ エヌ．ベー． 予測バイオマーカーのためのアッセイ

Also Published As

Publication number Publication date
PL3268493T3 (pl) 2022-05-09
IL254119A0 (en) 2017-10-31
EP3268493A2 (en) 2018-01-17
KR20170136525A (ko) 2017-12-11
WO2016145308A2 (en) 2016-09-15
DK3268493T3 (da) 2022-03-07
RS62972B1 (sr) 2022-03-31
SI3268493T1 (sl) 2022-04-29
MA45480A (fr) 2018-01-17
US20160304962A1 (en) 2016-10-20
HRP20220128T1 (hr) 2022-04-29
LT3268493T (lt) 2022-03-10
JP2018507702A (ja) 2018-03-22
CN107567502A (zh) 2018-01-09
PT3268493T (pt) 2022-04-13
EP3268493B1 (en) 2022-01-05
HUE058025T2 (hu) 2022-06-28
CA2979226A1 (en) 2016-09-15
ES2905163T3 (es) 2022-04-07
WO2016145308A3 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
CY1125020T1 (el) Mrna δεικτες βασιζομενοι σε ολικο αιμα για την προβλεψη του καρκινου προστατη και μεθοδοι ανιχνευσης αυτων
ZA202000935B (en) Methods and materials for assessing and treating cancer
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
NZ714049A (en) Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
EP3385717A3 (en) Methods of detecting prostate cancer
CY1124140T1 (el) Διαγνωστικοi δεικτες για την θεραπευτικη αντιμετωπιση υπερπλαστικων διαταραχων των κυτταρων με αναστολεα τελομερασης
MA40636A (fr) Procédés pour détecter le cancer de la prostate
MX2020007771A (es) Metodos para la supervision de la deteccion y el tratamiento de cancer de colon.
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
MX2018009112A (es) Metodo para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cancer mediante la medicion del nivel de un biomarcador plasmatico.
MX2019002932A (es) Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
SG11202003391XA (en) Method for assessing the risk of cutaneous adverse drug reactions induced by anti-epileptic drug lamotrigine, detection reagent thereof and use thereof
TR201407357A2 (tr) Prostat kanserinin tekrarlama potansiyelini tahmin yöntemi.
EA202090439A1 (ru) Способы и материалы для оценки и лечения рака
UA95581U (uk) Спосіб прогнозування зрощення перелому
UA99752U (uk) Спосіб прогнозування гематологічної токсичності хіміотерапії у хворих на рак грудної залози
UA96046U (uk) Спосіб прогнозування зрощення перелому
UA96045U (uk) Спосіб прогнозування зрощення перелому
UA95625U (uk) Спосіб прогнозування зрощення перелому
PL410049A1 (pl) Sposób wykrywania zwiększonego ryzyka zachorowania na raka skóry oraz zastosowania genotypowego wariantu genu GRHL3